DUBLIN--(BUSINESS WIRE)--
Research and Markets has announced the addition of the "Global Neurostimulation Device Market Size, Share, Development, Growth and Demand Forecast to 2022" report to their offering.
The global neurostimulation device market accounted for $5,656.1 million revenue in 2015 and it is expected to grow at a CAGR of 12.9% during 2016-2022. Between the two types, the implantable/internal segment held the larger share of about 84.0% in the global market in 2015. Among the various applications, the pain management segment held the largest share of about 60.8% during the same year. The global neurostimulation device market is witnessing high growth, due to increasing geriatric population, and increase in incidents of neurological disorders. In addition, the prevalence of chronic pain and neurological disorders is also increasing globally, due to which the demand for better neurostimulation device is increasing.
Some of the key companies operating in the global neurostimulation device market include Aleva Neurotherapeutics SA, St. Jude Medical Inc., Medtronic PLC, Boston Scientific Corporation, LivaNova PLC, Cochlear Ltd., Neuropace Inc., Neurosigma Inc., MED-EL GmbH, Synapse Biomedical Inc., Neuronetics Inc., NDI Medical LLC, EnteroMedics Inc., and ImThera Medical.
Key Topics Covered:
1. Research Scope & Methodology
2. Executive Summary
3. Market Outlook
4. Global Neurostimulation Device Market Size And Forecast (2012-2022)
5. Global Neurostimulation Device Market, By Type
6. Global Neurostimulation Device Market, By Application
7. Global Neurostimulation Device Market, By Geography
8. Competitive Positioning And Market Share Analysis
9. Company Profiles And Strategic Developments
10. Appendix
For more information about this report visit http://www.researchandmarkets.com/research/75pjmk/global

View source version on businesswire.com: http://www.businesswire.com/news/home/20161201006068/en/